MDNA

Medicenna Therapeutics (MDNA)

Medicenna Therapeutics Corporation

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:MDNA

1 2 3 4 5 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/15	05:29	Edgar (US Regulatory)	Form 15-12G - Securities registration termination [Section 12(g)]	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2024/05/15	04:42	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2024/05/14	03:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2024/05/01	04:07	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2024/04/27	04:28	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2024/04/26	03:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2024/04/23	05:40	Edgar (US Regulatory)	Form AW - Amendment Withdrawal Request	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2024/04/17	06:05	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2024/04/17	06:05	Edgar (US Regulatory)	Form F-3/A - Registration statement by foreign private issuers: [Amend]	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2024/04/17	06:04	Edgar (US Regulatory)	Form F-10POS - Post-effective amendment to a F-10EF registration	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2024/04/10	03:05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2024/04/05	03:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2024/02/14	21:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2024/01/25	06:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2024/01/10	00:33	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2024/01/05	23:06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2023/12/23	04:13	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2023/11/09	22:56	GlobeNewswire Inc.	Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2023/11/09	00:29	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2023/11/06	21:00	GlobeNewswire Inc.	Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2023/11/04	01:00	GlobeNewswire Inc.	Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2023/10/27	20:55	GlobeNewswire Inc.	Medicenna Announces Nasdaq Delisting and Cutback of Management Team	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2023/10/26	04:51	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2023/10/25	20:00	GlobeNewswire Inc.	Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2023/10/24	20:18	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2023/10/24	20:15	GlobeNewswire Inc.	Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2023/10/10	21:57	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2023/10/10	20:07	GlobeNewswire Inc.	Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2023/10/04	06:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MDNA	Medicenna Therapeutics Corporation
2023/10/03	20:00	GlobeNewswire Inc.	Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy	NASDAQ:MDNA	Medicenna Therapeutics Corporation